Published in
American Society of Clinical Oncology, Journal of Clinical Oncology, 2023
DOI: 10.1200/jco.23.01696
Links
Tools
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Journal article published in 2023 by
Lisa B. Leypoldt 
,
Diana Tichy ,
Britta Besemer,
Mathias Hänel,
Marc S. Raab ,
Christoph Mann ,
Markus Munder ,
Hans Christian Reinhardt,
Axel Nogai,
Martin Görner,
Yon-Dschun Ko,
Maike de Wit,
Hans Salwender ,
Christof Scheid ,
Ullrich Graeven
and other authors.
,
Diana Tichy ,
Britta Besemer,
Mathias Hänel,
Marc S. Raab ,
Christoph Mann ,
Markus Munder ,
Hans Christian Reinhardt,
Axel Nogai,
Martin Görner,
Yon-Dschun Ko,
Maike de Wit,
Hans Salwender ,
Christof Scheid ,
Ullrich Graeven
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
High, sustainable MRD negativity rates with Isa-KRd in newly diagnosed high-risk multiple myeloma (CONCEPT trial)